Author： Johnson N.J. Lane R.
Publisher： Elsevier
ISSN： 0924-977X
Source： European Neuropsychopharmacology, Vol.5, Iss.3, 1995-09, pp. : 314-315
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Basiliximab confers significant clinical benefit for marginal cost
Inpharma, Vol. 1, Iss. 1374, 2003-01 ,pp. :
Access to resources
Recommend
Olanzapine - clinical benefit accounts for cost savings
Inpharma, Vol. 1, Iss. 1275, 2001-01 ,pp. :
Basiliximab confers significant clinical benefit for marginal cost
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 399, 2003-01 ,pp. :
Olanzapine - clinical benefit accounts for cost savings
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 300, 2001-01 ,pp. :